BEGIN:VCALENDAR PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN VERSION:2.0 BEGIN:VEVENT DESCRIPTION:With Merck's oral PCSK9 inhibitor demonstrating strong phase 3 trial results\, J AND J's IL23R antagonist peptide continuing its phase 3 journey\, and Chugai advancing peptides into the intracellular space\, peptide therapeutics are firmly back on the map as the next modality disr upting drug discovery and development.\n\nThis includes exploring peptide structure prediction using AI/ML technologies\, designing orally bioavai lable and cell membrane-permeable peptides using structure-based molecula r design\, harnessing mRNA display and DNA-encoded libraries for peptide discovery\, optimizing peptide synthesis\, integrating formulation consid erations at the discovery stage\, and investigating peptides as drug deli very vehicles.\n\nThe 2nd Peptide-Based Therapeutics Summit returns to Bo ston as your most comprehensive\, industry-dedicated forum for overcoming the unique drug discovery challenges of peptide-based therapeutics and p owering up your development pipelines to achieve 2025/26 milestones.\n\nA s this revitalized space reaches a critical tipping point\, join the conv ersation on how advancements in computational\, medicinal chemistry\, and formulation technologies are driving peptide pipeline progression from h it to lead.\n\nUse this as your pulse-check opportunity to stay abreast o f peptide drug discovery news\, build meaningful partnerships\, and super charge cutting-edge peptide-based therapies from concept to clinic and be yond!\n\n \;\n\nTime: 8:00 AM - 5:00 PM\n DTEND:20250403T170000 DTSTAMP:20260512T232257Z DTSTART:20250401T080000 LOCATION:Hilton Boston Back Bay\, 40\, Dalton Street\, Boston\, Massachuse tts\, 02115\, SEQUENCE:0 SUMMARY:With Merck's oral PCSK9 inhibitor demonstrating strong phase 3 tri al results\, J AND J's IL23R antagonist peptide continuing its phase 3 jo urney\, an... UID:d67d0d9a-3229-41bd-b1ce-d20a69764564 END:VEVENT END:VCALENDAR